Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Argenx SE    ARGX   NL0010832176

ARGENX SE

(ARGX)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 12/01 03:59:58 pm
238.3 EUR   -0.38%
11/23ARGENX : Enters Into Agreement To Acquire Priority Review Voucher
AQ
11/23argenx Enters Into Agreement To Acquire Priority Review Voucher
GL
11/16ARGENX SE : Crossing thresholds
CO
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
11/25/2020 11/26/2020 11/27/2020 11/30/2020 12/01/2020 Date
222.6(c) 229.6(c) 235(c) 239.2(c) 239.6(c) Last
48 442 31 961 98 396 212 067 77 805 Volume
+1.74% +3.14% +2.35% +1.79% +0.17% Change
More quotes
Financials
Sales 2020 59,2 M 70,7 M 70,7 M
Net income 2020 -469 M -561 M -561 M
Net cash position 2020 1 358 M 1 623 M 1 623 M
P/E ratio 2020 -25,1x
Yield 2020 -
Sales 2021 113 M 135 M 135 M
Net income 2021 -455 M -544 M -544 M
Net cash position 2021 1 345 M 1 608 M 1 608 M
P/E ratio 2021 -27,8x
Yield 2021 -
Capitalization 11 324 M 13 534 M 13 538 M
EV / Sales 2020 168x
EV / Sales 2021 88,5x
Nbr of Employees 186
Free-Float 99,6%
More Financials
Company
argenx SE is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical... 
More about the company
Notations Surperformance© of argenx SE
Trading Rating : Investor Rating :
More Ratings
All news about ARGENX SE
11/23ARGENX : Enters Into Agreement To Acquire Priority Review Voucher
AQ
11/23argenx Enters Into Agreement To Acquire Priority Review Voucher
GL
11/16ARGENX SE : Crossing thresholds
CO
11/16ARGENX SE : Corporate Officers and Executives' transactions in the company's sec..
CO
11/12ARGENX SE : Crossing thresholds
CO
11/09ARGENX : to Participate in Upcoming Virtual Investor Conferences
AQ
11/09argenx to Participate in Upcoming Virtual Investor Conferences
GL
11/05ARGENX SE : Corporate Officers and Executives' transactions in the company's sec..
CO
11/04ARGENX SE : Corporate Officers and Executives' transactions in the company's sec..
CO
11/04ARGENX SE : Corporate Officers and Executives' transactions in the company's sec..
CO
11/03ARGENX SE : Corporate Officers and Executives' transactions in the company's sec..
CO
10/29ARGENX SE : Corporate Officers and Executives' transactions in the company's sec..
CO
10/23ARGENX SE : Press Release
CO
10/23ARGENX SE : 3rd quarter results
CO
10/22ARGENX : Q3 FY20 Earnings conference call and audio webcast
PU
More news
News in other languages on ARGENX SE
11/12Corona kann Evotec kaum etwas anhaben - Prognose bestätigt
10/2320 valeurs de croissance cotées en Europe
10/22ARGENX SE : -6% après la pause de deux analystes
10/13Staatsfonds aus Abu Dhabi steigt über Kapitalerhöhung bei Evotec ein
10/01TOUR DU MONDE DES INDICES : l’Aristocratie souffre sur le S&P500, la Santé sauve..
More news
Chart ARGENX SE
Duration : Period :
argenx SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARGENX SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 240,99 €
Last Close Price 239,20 €
Spread / Highest target 21,2%
Spread / Average Target 0,75%
Spread / Lowest Target -10,1%
EPS Revisions
Managers
NameTitle
Tim van Hauwermeiren Chief Executive Officer & Executive Director
Peter K. M. Verhaeghe Chairman
R. Keith Woods Chief Operating Officer
Eric Castaldi CFO & Principal Accounting Officer
Hans J. W. de Haard Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ARGENX SE66.57%13 534
GILEAD SCIENCES, INC.-6.63%75 249
VERTEX PHARMACEUTICALS4.02%58 953
REGENERON PHARMACEUTICALS37.43%54 255
WUXI APPTEC CO., LTD.56.53%37 916
BIONTECH SE266.71%26 484